BiotechTube

linezolid

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Burns

Conditions

Burns

Trial Timeline

May 1, 2006 → Jan 1, 2007

NCT ID
NCT00255996

About linezolid

linezolid is a phase 1 stage product being developed by Pfizer for Burns. The current trial status is completed. This product is registered under clinical trial identifier NCT00255996. Target conditions include Burns.

What happened to similar drugs?

3 of 6 similar drugs in Burns were approved

Approved (3) Terminated (3) Active (3)
✅Ceftolozane/tazobactamMerckApproved
✅Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
✅Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
🔄Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
🔄NexoBrid + Gel VehicleMediWoundPhase 3
🔄NexoBridMediWoundPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT01805284ApprovedCompleted
NCT01040585Pre-clinicalWithdrawn
NCT00255996Phase 1Completed
NCT01564758Pre-clinicalCompleted
NCT00147511ApprovedCompleted
NCT00150332Phase 3Completed

Competing Products

12 competing products in Burns

See all competitors
ProductCompanyStageHype Score
R-Pdf/Gbb 0.01% gelJohnson & JohnsonPhase 2
31
Ceftolozane/tazobactamMerckApproved
35
Somatropin + 0.09% Saline SolutionPfizerPhase 2/3
38
Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
37
cP12United TherapeuticsPhase 2
39
cNP8United TherapeuticsPhase 1
26
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
32
Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL ThrombinBaxterPhase 1/2
29
I-020502BaxterPhase 2
32
Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
25
NexoBrid + Gel VehicleMediWoundPhase 3
30
NexoBridMediWoundPhase 3
30